You are here

nipocalimab

J&J’s nipocalimab shows promise in Phase II Sjögren’s disease trial

Clinical Trials Arena

Fri, 11/15/24 - 11:02 am

Sjögren’s syndrome

J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker

Fierce Biotech

Tue, 10/15/24 - 10:10 am

myasthenia gravis

J&J submits touted autoimmune disease drug for FDA approval

BioPharma Dive

Thu, 08/29/24 - 11:24 am

myasthenia gravis

J&J unwraps pivotal data on $6.5B autoimmune asset as it prepares to crash argenx and UCB's party

Fierce Biotech

Mon, 07/1/24 - 11:23 am

myasthenia gravis

clinical trials

J&J’s $6.5B Momenta Buy Pays Off With Phase II Sjögren’s Disease Win

BioSpace

Mon, 06/17/24 - 11:36 am

clinical trials

Sjögren’s syndrome

J&J targets rare maternal-fetal diseases: 'We're going for this. No one else has.'

Fierce Biotech

Tue, 04/2/24 - 11:49 am

maternal-fetal diseases

J&J’s growing rare disease focus brings a potential multi-use treatment to the table

Pharma Voice

Thu, 03/7/24 - 05:29 pm

myasthenia gravis

J&J's immune disorder drug succeeds in mid and late-stage studies

Reuters

Mon, 02/5/24 - 10:14 am

autoimmune disease

clinical trials

myasthenia gravis

Sjögren’s syndrome

Janssen’s antibody drug shows phase 2 potential in rheumatoid arthritis

Biopharma Reporter

Thu, 11/9/23 - 09:55 am

rheumatoid arthritis

clinical trials

After spending $6.5B for Momenta, J&J readies 'pipeline in a product' for pivotal year

Fierce Biotech

Mon, 02/27/23 - 10:09 am

Momenta Pharmaceuticals

J&J clears PhII for rare blood disorder with drug from $6.5B Momenta buyout

Endpoints

Mon, 02/6/23 - 10:41 am

clinical trials

J&J’s $5bn projects have much to prove

EP Vantage

Wed, 10/19/22 - 10:37 am

Rybrevant/lazertinib

Janssen Recruiting for Phase III Trials of Potential Myasthenia Gravis Game Changer

BioSpace

Mon, 06/20/22 - 10:57 am

clinical trials

myasthenia gravis